STING agonist, SMA-2, inhibits clear cell renal cell carcinoma through improving tumor microenvironment

Mol Cell Biochem. 2024 Apr 9. doi: 10.1007/s11010-024-04970-w. Online ahead of print.ABSTRACTClear cell renal cell carcinoma (ccRCC) is the most prevalent and lethal subtype of kidney cancer, patients with ccRCC usually have very poor prognosis and short survival. Therefore, it is urgent to develop more effective therapeutics or medications to suppress ccRCC progression. Here, we demonstrated that STING agonist, MSA-2 significantly inhibits tumor progress and prolongs the survival of ccRCC mice by promoting cytokines secretion. Moreover, MSA-2 triggered the trafficking and infiltration of CD8+ T cells, supported by the generation of a chemokine milieu that promoted recruitment and modulation of the immunosuppressive TME in ccRCC. These findings suggest that MSA-2 potentially serves an effective and preferable adjuvant immunotherapy of ccRCC.PMID:38592428 | DOI:10.1007/s11010-024-04970-w
Source: Molecular and Cellular Biochemistry - Category: Biochemistry Authors: Source Type: research